GB Sciences files 3 patents for new cannabis-based therapies

GB Sciences, a Nevada-based biopharma company, is exploring the potential of cannabinoids in medicine with new cannabis-based therapies.

While much has been made over GW Pharmaceutical’s epilepsy treatment programs using CBD solutions, there are still hundreds of other areas where cannabis may be able to help patients as well. That is where GB Sciences comes in, and they have filed “three provisional patent applications containing formulations designed to tackle neurological disorders, inflammatory disorders, and chronic pain”.


The Process

With cannabis legalized for recreational use in their home state of Nevada in November 2016 and relaxing federal regulations as more and more realize the medical value of cannabinoids, GB Sciences is uniquely positioned in the burgeoning cannabis-based therapies scene with several advantages over other companies.

When choosing a patient group to develop therapeutics for, GB Sciences identifies patient groups that are overlooked by other companies, then uses cell-based modelling to rapidly analyze thousands of potential combinations to find solutions, and finally, uses its own standardized raw materials for R&D and clinical products as it has a state license to grow, extract, and sell cannabis.

This approach saves GB Sciences time, cuts costs, and keeps everything in-house, ensuring the company is able to monitor and control every step of the process.


The Patents

The three patent applications filed by the company cover different areas where cannabis-based therapies have a lot of potential: neurological disorders, inflammatory diseases, and chronic pain.

The first patent application is for “cannabis-based complex mixtures designed to treat neurological disorders like Parkinson’s disease, Lewy Body dementia, Huntington’s disease, dementia, and Alzheimer’s disease”. The second patent “covers cannabis-based complex mixtures designed to treat inflammatory diseases, such as osteoarthritis, rheumatoid arthritis, Crohn’s disease, IBD, asthma, COPD, and other conditions”.

For the first two patents, the team at GB Sciences focused on finding common mechanisms and pathways to maximize the applications of the therapeutics for the given area.

The third patent “describes the use of a myrcene-containing complex mixture for the treatment of heart disease”, which is the first new formulation for heart disease in over two decades.


What’s Next?

With its drug development pipeline, competitive advantages, three patent applications, and focus on the commonalities of medical conditions, GB Sciences is set to maximize the benefits of their therapeutics for as many patients as possible.